NEWS & Join Us

“The true sign of intelligence is not knowledge but imagination." — Albert Einstein

\

Tavotek Pivotal Asset Tavo412 Presented at 2022 AAPS National Biotech Conference

  • Author:
  • Origin:
  • Time of issue:2022-05-12
  • Views:250

Tavotek Pivotal Asset Tavo412 Presented at 2022 AAPS National Biotech Conference

  • Author:
  • Origin:
  • Time of issue:2022-05-12
  • Views:250

(LOWER GWYNEDD, Pennsylvania, May 12, 2022)  Tavotek Biotherapeutics, a fast-growing biopharmaceutical company, announced that its pivotal oncology asset Tavo412 was presented today at the 2022 AAPS National Biotechnology Conference in Anaheim, California.  

 

American Association of Pharmaceutical Scientists (AAPS) is an association with nearly 9,000 scientists interested in advancing the development of therapies to address global medical needs. The AAPS National Biotechnology Conference is a premier event that provides an engaging environment where pharmaceutical scientists can exchange interesting ideas, showcase their latest research, and network with other professionals within the industry.

 

Dr. Chao Han, Head of Tavotek US, presented the design and unique features of Tavo412 at this prestigious national scientific conference. 

 

“I am very excited to present the great features of Tavo412 to our fellow pharmaceutical scientists at this premier conference,” said Dr. Han. “Tavo412 is a uniquely designed multi-specific biologics and engineered by our proprietary novel TavoSelect and TavoPrecise platforms. Tavo412 employs multiple target avidity-driven effects in the tumor environment to maximize anti-tumor efficacy. Tavo412 has excellent activities against many difficult-to-treat cancers in multiple in vitro and in vivo models that include triple negative breast cancer, pancreatic cancer and gastric cancer. We are excited to bring Tavo412 to Phase 1 clinical testing later this year.”

 

About Tavotek

Tavotek is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases. For more information, please visit www.tavotek.com.

 

Related News

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Announces FDA Clearance of FIH Clinical Trial for TAVO412
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Launching First-In-Human Study of Two Assets In 2022
NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS
Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

727 Norristown Road, 3 Spring House Innovation Park Suite 101, Lower Gwynedd, Pennsylvania 19002

China. Suzhou. Suzhou Industrial Park. Unit 405, Building C2, No. 218, Xinghu Street

© 2022 Tavotek Biotherapeutics All rights reserved.   (267) 405-9426

© 2022 Tavotek Biotherapeutics All rights reserved.(267) 405-9426